You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
The company is developing dedicated product lines for next-generation sequencing that incorporate a thermal cycler capable of 35-minute PCR.
The assay has been developed for research purposes, as a higher-throughput and lower-cost alternative to similar commercially available tests.
The firm plans to add more oncology tests, NIPTs and newborn screening assays through in-house development and partnerships with third-party assay makers.
The firm's technology can perform in-droplet centrifugation, 10-second cell lysis, and sound wave-based PCR on the surface of an inexpensive polymer chip.
The new chip enables the firm's digital PCR system to test up to 240 samples per day, and also uses lower volumes of sample input.
OmniVis is developing the assay for cholera detection in environmental samples while the lab that created it is working toward a paper-based HIV test.
New funding will support genome-wide studies to uncover loci conferring immunity to a live-attenuated Plasmodium vaccine.
The firm also continues to use its methylation-specific PCR technology to develop assays for partners in the oncology space.
New funding will support assay development and lab space to offer test services, and ultimately a test kit using the firm's resistance database.
Researchers showed that the test had equivalent results to a lab-based assay and has the potential for a faster turnaround time.
Los Angeles brought and settled a civil enforcement action against the makers of an at-home test for SARS-CoV-2, NPR reports.
The Guardian reports that Cancer Research UK is cutting its research funding by £44 million.
Technology Review examines factors affecting SARS-CoV-2 testing turnaround times.
In PNAS this week: mapping of ancient human migrations in Europe, recurrent gene fusion in breast cancer, and more.